Navigation Links
Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
Date:4/26/2009

/Ribavirin (IR) Therapy: Final Results of the EPIC3 Cirrhosis Maintenance Trial(1)

The large EPIC3 clinical study program includes a prospective trial designed to assess the efficacy and tolerability of long-term, low-dose maintenance therapy with PEGINTRON 0.5 mcg/kg/week in patients who previously failed treatment with any alfa-interferon plus ribavirin combination therapy. A total of 631 patients were randomized to PEGINTRON or observational control. Of these, 454 patients were from the retreatment study portion of the EPIC3 program and 172 were direct enrollers into the maintenance study. The primary efficacy measure for the study was time to development of first clinical event, defined as liver decompensation (variceal bleeding, Child-Pugh class C, grade 2 or higher hepatic encephalopathy, ascites requiring therapeutic paracentesis and/or additional therapy), development of hepatocellular carcinoma (HCC), liver transplantation or death. All events other than transplantation and death were adjudicated by an independent committee of experts blinded to the study arm. The secondary efficacy analyses included time to disease progression, including additional events of Child-Pugh class B, emergence of varices and enlargement of pre-existing varices requiring additional therapy.

In the primary efficacy analysis, 36 patients in the control arm and 27 in the treatment arm had clinical events (P=0.14), a non-statistically significant difference. However, in the secondary efficacy analysis there were 87 clinical events in the control arm and 63 in the treatment arm (P=0.01), a statistically significant difference. The main events causing the difference on secondary analysis were emergence or enlargement of varices (43 control vs. 16 treatment). In patients with pre-existing esophageal varices (n=82) there were significantly more events (n=14) in the observation arm compared to the treatment arm (n=4) (P=0.01). Overall the safet
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Germany , and MARSEILLE, ... , Exclusive global license from University ... mutations, including next-generation sequencing (NGS) gene panels, for blood ... targeted by new test, indicate favorable prognosis for patients ... QIAGEN sees potential for developing companion diagnostics to ...
(Date:7/24/2014)... July 24, 2014  IRIDEX Corporation (NASDAQ: ... second quarter 2014 financial results after the market closes ... with the release, the Company will host a conference ... Eastern Time on Thursday, July 31, 2014 ... other business developments. Interested parties may access ...
(Date:7/24/2014)... 24, 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a ... announced its financial results for the second quarter ended June ... , Total revenues of $6.5 million in the second quarter ... in 2013 , Total revenues of $13.3 million for ... 78% over the same period in 2013 , Total ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... New "Oxygen Sandwich" Device is First to Mimic Natural ... the major challenges to islet,cell transplantation as the treatment ... donor tissue supply. Patients often need a re-infusion of ... donor pancreas is,needed to provide the fragile islet cells ...
... Ozarelix Was Maintained For ... Up To Six Months, ... IRVINE, Calif., Sept. 5 Spectrum,Pharmaceuticals, Inc., (Nasdaq: SPPI ) ... drug candidate for the,treatment of benign prostatic hypertrophy (BPH), at the 29th ...
Cached Medicine Technology:Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells 2Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 2Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 3Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 4Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 5
(Date:7/25/2014)... July 25, 2014 Ticket Down ... the board for the Guinness International Champions Cup match ... FC at Soldier Field on Sunday, July 27th. ... customer appreciation promo/coupon/offer code SOCCER-2014 for added savings. , ... for diehard soccer fans in North America. Countless international ...
(Date:7/25/2014)... The Gerontological Society of America (GSA) ... field of aging has chosen Heather M. ... California, Davis, as the 2014 recipient of the ... distinguished honor, presented by GSA,s Health Sciences Section, ... in recognition of outstanding and sustained contribution to ...
(Date:7/25/2014)... Reproductive Science Center (RSC) of New ... Luzzo, Lead Physician at RSC Rhode Island, received the ... in fertility care and community outreach issued by Providence ... PBN Awards ceremony held July 24th at Salve Regina ... highly regarded, emerging leaders in their field were recognized ...
(Date:7/25/2014)... Houston, TX (PRWEB) July 25, 2014 ... Annual Family Fun Fest on Sunday, July 27 at ... franchises include Memorial, Copperfield, Katy, Pearland, Friendswood, Spring, ... location in The Heights. , “We’re thrilled to ... this year,” said Heather Belcher who owns the Sugarland-Missouri ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 AttorneyOne.com, a recognized ... latest information from the FDA on Ibuprofen and Oxcarbazepine ... that one lot of Ibuprofen and one lot of Oxcarbazepine ... due to mislabeled packaging. Oxcarbazepine is used for the treatment ... , The reason for the recall is that Lot ...
Breaking Medicine News(10 mins):Health News:Liverpool FC vs. Olympiacos FC Tickets Soldier Field: Ticket Down Slashes Ticket Prices for Guinness International Champions Cup in Chicago on Sunday, July 27th 2Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2
... Effect Sept. 11; Online Resources and Helpline Now,Available, ... date of Pennsylvania,s Clean Indoor Air Act fast approaching, ... to help,them comply with the law that will ban ... portion of casino floors., Guidance and a downloadable ...
... MBF Healthcare,Acquisition Corp. (Amex: MBH ), ... today the amendment of the Stock Purchase,Agreement ... Solutions,Holdings, Inc. ("CHS"), based on the signed ... (the "Stock Purchase Agreement"). CHS is a,privately-owned, ...
... 2 Ethiopia,s Ministry of Health,recently signed a ... at helping the country reach the U.N.,s Millennium,Development ... do so., The agreement provides a framework ... Ethiopia and the partners who are,contributing to the ...
... even a year after routine was stopped, study says ... may help treat memory problems in adults, according to ... 138 people age 50 and older at increased risk ... led to modest improvements in cognitive function in adults ...
... benefit of nation,s 1st such law, passed in 2004 , , ... ill kids have made use of California,s pioneering paid family ... it exists, according to researchers at the Rand Corp. ... law. It is funded by employees through an automatic payroll ...
... Normal Weight Obesity: A Real Health Risk, ... are,highlights from the September issue of Mayo ... as often as you wish. Mayo Clinic ... for a fee.,Include the following subscription information ...
Cached Medicine News:Health News:PA Department of Health Reminds Businesses to Prepare to Implement Clean Indoor Air Act 2Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 2Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 3Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 4Health News:Ethiopia First Nation to Sign National Health Partnership Compact 2Health News:Exercise May Help Prevent Age-Related Memory Loss 2Health News:Paid Family Leave Program Goes Mostly Unused 2Health News:September 2008 Mayo Clinic Women's HealthSource Highlights Normal Weight Obesity, Regular Exercise and Cholesterol 2Health News:September 2008 Mayo Clinic Women's HealthSource Highlights Normal Weight Obesity, Regular Exercise and Cholesterol 3Health News:September 2008 Mayo Clinic Women's HealthSource Highlights Normal Weight Obesity, Regular Exercise and Cholesterol 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: